Dr. Michael A. Davies on Identifying Patients With Melanoma at Risk for Developing Brain Metastases

Video

​Michael A. Davies, MD, PhD, discusses the importance of identifying which patients diagnosed with melanoma are at the highest risk for developing brain metastases.

Michael A. Davies, MD, PhD, associate professor, deputy chair, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of identifying which patients diagnosed with melanoma are at the highest risk for developing brain metastases. He said this identification process is equally important in patients with early-stage disease as it is in patients with advanced melanoma.

Related Videos
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Hussein Tawbi, MD, PhD, smiling at camera.
Related Content
FDA Clears IND for Tumor Infiltrating Lymphocyte Therapy

FDA Clears IND for Tumor Infiltrating Lymphocyte Therapy

November 29th 2023
Article

A phase 1/2 study of KSQ-001EX will commence at MD Anderson Cancer Center following this investigational new drug approval from the FDA.

Read More

Understanding and Treating Mucosal Melanoma

Understanding and Treating Mucosal Melanoma

April 14th 2023
Podcast

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

Listen

Behind the FDA Approval of Enzalutamide for Prostate Cancer

Behind the FDA Approval of Enzalutamide for Prostate Cancer

November 22nd 2023
Article

Neal Shore, MD, FACS, discussed the phase 3 EMBARK trial and what the FDA approval of enzalutamide means for the prostate cancer treatment landscape.

Read More

A Look Inside the Toolbox for BRAF-Mutant Metastatic Melanoma

A Look Inside the Toolbox for BRAF-Mutant Metastatic Melanoma

February 15th 2022
Podcast

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

Listen

Sotorasib and Panitumumab Outperforms SOC in KRAS G12C+ mCRC

Sotorasib and Panitumumab Outperforms SOC in KRAS G12C+ mCRC

November 15th 2023
Article

In an interview with Targeted Oncology, City of Hope cancer center’s Marwan Fakih, MD, further discussed the findings from this phase 3 trial and future directions for evaluating this combination.

Read More

Johnson Analyzes Combination Immunotherapy in the First Line in Advanced Melanoma

Johnson Analyzes Combination Immunotherapy in the First Line in Advanced Melanoma

November 15th 2023
Article

During a Targeted Oncology™ Case-Based Roundtable™ event, Douglas B. Johnson, MD, MSCI, reviewed data for safety and efficacy of immune checkpoint inhibition in patients with metastatic melanoma.

Read More